Choking is one of the most common medical emergencies in everyday life, yet it is often underestimated. When a foreign... Read more
Category: Uncategorized
Amgen kicks off 2026 with $840M acquisition of Dark Blue Therapeutics
U.S. biotech giant Amgen has agreed to acquire Oxford-based Dark Blue Therapeutics in a deal valued at up to $840... Read more
Day One Biopharmaceuticals concludes acquisition of Mersana Therapeutics
On January 8, 2026, Day One Biopharmaceuticals announced the formal completion of its acquisition of Mersana Therapeutics following the satisfaction... Read more
Eli Lilly secures $1.3 billion research deal with Nimbus to advance obesity pipeline
Pharmaceutical giant Eli Lilly has entered into a new research and licensing agreement with Nimbus Therapeutics. The partnership aims to... Read more
FDA approves new Fibryga formulation for Acquired Fibrinogen Deficiency
On January 8, 2026, the U.S. Food and Drug Administration (FDA) granted approval for a new 2-gram (g) formulation of... Read more
Eli Lilly acquires Ventyx for $1.2B to secure next-generation oral inflammation therapies
Eli Lilly has officially announced an agreement to acquire Ventyx Biosciences for $14 per share, totaling $1.2 billion. This strategic... Read more
Next-generation HER2 agent demonstrates superiority in gastric cancer treatment
New data from the phase 3 Herizon-Gea-01 clinical trial signals a potential paradigm shift in the first-line treatment of HER2-positive... Read more
Bayer launches patent infringement lawsuits against three major COVID-19 vaccine makers
The German chemical and pharmaceutical giant Bayer has filed separate lawsuits against Moderna, Johnson & Johnson (J&J), and the Pfizer-BioNTech... Read more
Eli Lilly dominates Clarivate’s 2026 list of transformative drugs
Clarivate’s annual "Drugs to Watch 2026" report has identified 11 potential blockbusters, with Eli Lilly’s cardiometabolic therapies taking center stage.... Read more









